A Novel Nutraceutical Drug for OA Treatment
Abstract
Over 27 million Americans are currently diagnosed with osteoarthritis (OA), and OA is our nation's leading cause of pain and disability. Medically linked retirement caused by musculoskeletal disorders such as OA increased nearly 10-fold among active military service members between 2003 to 2009. The rate of OA in military populations is twice as high as that in non-military populations. Neither a disease-modifying OA drug nor a non-surgical cure presently exists. Therefore, it is extremely important to have a drug which mitigates OA disease progression and relieves OA pain, with minimal, if any, adverse effects. The aim of the current project is to determine the therapeutic efficacy of a novel botanical drug using a canine model of post-traumatic OA, a large animal model that replicates the pathology and symptoms of human OA. Successful completion of the proposed studies will provide critical evidence to the Food and Drug Administration for approval for human clinical trials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1089983
Entities
People
- Hui B. Sun
Organizations
- Albert Einstein College of Medicine